IMPACT OF DEVELOPMENT ON PROTEIN UTILIZATION AND GROWTH
发育对蛋白质利用和生长的影响
基本信息
- 批准号:8356656
- 负责人:
- 金额:$ 1.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-12-01 至 2011-11-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAdolescenceAgeAnimalsBirthBody CompositionClinical ResearchDataDevelopmentDietDual-Energy X-Ray AbsorptiometryEnteralEnteral FeedingExcretory functionFailureFamily suidaeFundingGestational AgeGrantGrowthHead circumferenceHigh PrevalenceHospitalsHumanInfantInfant DevelopmentIntakeLengthLeucineLifeLow Birth Weight InfantMeasurementMeasuresMetabolicMonitorMotorNational Center for Research ResourcesNeurodevelopmental DeficitNewborn InfantNitrogenNursery SchoolsNutritionalOutcomePerformancePopulationPregnancyPremature InfantPrincipal InvestigatorProteinsResearchResearch InfrastructureResourcesRodentSkinfold ThicknessSourceTestingTimeUnited States National Institutes of HealthWeightbasecostcritical periodfeedinghuman dataimprovedindexingneonateoxidationprotein degradationresponseurinaryyoung adult
项目摘要
This subproject is one of many research subprojects utilizing the resources
provided by a Center grant funded by NIH/NCRR. Primary support for the subproject
and the subproject's principal investigator may have been provided by other sources,
including other NIH sources. The Total Cost listed for the subproject likely
represents the estimated amount of Center infrastructure utilized by the subproject,
not direct funding provided by the NCRR grant to the subproject or subproject staff.
Despite improvements in nutritional management of low birth weight (LBW) infants over the past decade, most who weigh 1500g at birth, even if appropriate size for gestational age at birth, weigh less than and are shorter than the 10th percentiles of intrauterine standards at discharge (~36 wks post menstrual age) and many remain small as late as adolescence and young adulthood. While the consequences of the early growth failure are not known with certainty, there is evidence that it may contribute to the high prevalence of developmental deficits in this population. Studies are proposed to test the hypothesis that there is a finite period during which the human infant is capable of maximal utilization of protein for growth. Based on limited studies in infants and acute studies in animals, this period appears to encompass the latter part of gestation and the first few months post-term but it remains undefined. Corollary hypotheses, which also will be tested in human infants, are that maximizing protein intake during this finite period of enhanced sensitivity to protein intake will improve growth and, hence, reduce the subsequent growth and neurodevelopmental deficits of preterm infants. In toto, the proposed studies will determine if there is a finite period during which the human neonate can maximally utilize protein intake for growth as measured by whole body protein turnover and also will define this period. They also will determine if maximizing protein intake during this finite period improves early growth without imposing unacceptable metabolic consequences and if this improved growth reduces subsequent growth and neurodevelopmental deficits. Overall, the findings of this project are expected to contribute to further improvements in nutritional management and, hence, outcome of LBW infants.
The overall hypothesis to be addressed by this study is that there is a finite period early in life during which the newborn is uniquely able to utilize protein intake for growth. if true, as suggested by data from human infants as well as data from acute feeding studies in rodents and swine, maximizing protein in take during this finite period will enhance growth during this period, thereby reducing the long-term growth and neurodevelopmental deficits of preterm/low birth weight (LBW) infants.
This hypothesis will be addressed by achieving the following objectives:
1. To determine if there is a finite period during which the LBW infant responds maximally to protein intake and, if so, to define this period;
2. To determine if a higher protein intake during this (critical) period improves growth without imposing unacceptable metabolic consequences and decreases subsequent growth deficits of LBW infants;
3. To determine if a higher protein intake during this (critical) period improves subsequent neurodevelopmental performance of LBW infants.
SPECIFIC AIMS
1. To measure whole body protein turnover (using 1-13C-leucine), leucine oxidation and urinary nitrogen excretion serially in LBW infants fed protein intakes of ~3 g and ~4.0 g/kg-d from the time full enteral intake is tolerated until 4 months post-term. measurements will be made shortly after full enteral feedings are tolerated, at hospital discharge, at 40 weeks post-menstrual age (term), at 2 months post-term and at 4 months post-term. The end of the finite period of maximal response to protein intake will be defined by increases in 1-13C-leucine oxidation and urinary nitrogen excretion.
2. To monitor, through 18 months post-term, growth (weight, length, head circumference and skinfold thicknesses) and body composition (DXA) of LBW infants fed the above protein intakes through 4 months post-term, a regular post-discharge formula from 4-to-9 months post-term and a regular infant diet from 9-to-18 months post-term.
3. To determine neurodevelopmental indices (Preschool Langueag Scale, Fourth edition (PLS-4); Bayley Scales of Infant Development-II (MDI and PDI); Peabody Developmental Motor Scales (PBMS) of infants fed as described in Specific Aim 2 at 4, 12 and 18 months post-term.
这个子项目是利用资源的许多研究子项目之一。
由NIH/NCRR资助的中心拨款提供。对子项目的主要支持
子项目的首席调查员可能是由其他来源提供的,
包括美国国立卫生研究院的其他来源。为子项目列出的总成本可能
表示该子项目使用的中心基础设施的估计数量,
不是由NCRR赠款提供给次级项目或次级项目工作人员的直接资金。
尽管低出生体重(LBW)婴儿的营养管理在过去十年中有所改善,但大多数出生时体重为1500克的婴儿,即使出生时的大小适合胎龄,在出院时(月经后约36周)体重也低于或低于宫内标准的10%,而且许多人直到青春期和成年期都很小。虽然早期增长失败的后果尚不确定,但有证据表明,它可能导致这一人群中发育缺陷的高发。有人建议进行研究,以检验这一假设,即在有限的时期内,人类婴儿能够最大限度地利用蛋白质进行生长。根据对婴儿的有限研究和对动物的急性研究,这一时期似乎包括怀孕的后期和足月后的头几个月,但它仍然没有定义。也将在人类婴儿身上测试的推论是,在对蛋白质摄取的敏感度增强的有限时期内,最大限度地摄取蛋白质将促进生长,从而减少早产儿随后的生长和神经发育缺陷。总之,拟议的研究将确定是否存在一个有限的时期,在此期间,人类新生儿可以最大限度地利用蛋白质摄入量来促进生长,这是通过全身蛋白质周转来衡量的,并将定义这一时期。他们还将确定在这段有限的时间内最大限度地摄入蛋白质是否在不造成不可接受的代谢后果的情况下改善早期生长,以及这种改善的生长是否减少了随后的生长和神经发育缺陷。总体而言,预计该项目的结果将有助于进一步改善营养管理,从而有助于改善LBW婴儿的结局。
这项研究要解决的总体假设是,在生命早期有一个有限的时期,在这段时期内,新生儿能够独特地利用蛋白质摄取来生长。如果是真的,正如来自人类婴儿的数据以及来自啮齿动物和猪的急性喂养研究的数据所表明的那样,在这一有限的时期内最大限度地摄入蛋白质将促进这一时期的生长,从而减少早产/低出生体重(LBW)婴儿的长期生长和神经发育缺陷。
将通过实现以下目标来解决这一假设:
1.确定LBW婴儿对蛋白质摄入的最大反应是否存在一个有限的时间段,如果是,则定义该时间段;
2.确定在这一(关键)时期,较高的蛋白质摄入量是否在不造成不可接受的代谢后果的情况下改善生长,并减少LBW婴儿随后的生长缺陷;
3.确定在这一(关键)时期摄入更高的蛋白质是否会改善LBW婴儿随后的神经发育表现。
具体目标
1.连续测定蛋白质摄入量为~3g/kg·d~(-1)和~4.0g/kg·d~(-1)的LBW婴儿从完全肠道耐受至足月后4个月的全身蛋白质周转(用1-13C-亮氨酸)、亮氨酸氧化和尿氮排泄。测量将在完全肠道喂养耐受后不久、出院时、经后40周(足月)、足月后2个月和足月后4个月进行。对蛋白质摄入的最大反应的有限时期的结束将被定义为1-13C-亮氨酸氧化和尿氮排泄的增加。
2.通过产后4个月、产后4个月、产后4个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月、产后9个月
3.于产后4个月、12个月和18个月测定神经发育指标(学龄前儿童语言发育量表第四版(PLS4)、贝利婴儿发育量表II(MDI和PDI)、Peabody发育运动量表(PBMS))。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William C. Heird其他文献
Hyperammonemia resulting from intravenous alimentation using a mixture of synthetic <span class="small-caps">L</span>-amino acids: A preliminary report
- DOI:
10.1016/s0022-3476(72)80396-2 - 发表时间:
1972-07-01 - 期刊:
- 影响因子:
- 作者:
William C. Heird;John F. Nicholson;John M. Driscoll;John N. Schullinger;Robert W. Winters - 通讯作者:
Robert W. Winters
Impaired synthesis of DHA in patients with X-linked retinitis pigmentosa
- DOI:
10.1016/s0022-2275(20)30271-6 - 发表时间:
2001-09-01 - 期刊:
- 影响因子:
- 作者:
Dennis R. Hoffman;James C. DeMar;William C. Heird;David G. Birch;Robert E. Anderson - 通讯作者:
Robert E. Anderson
Improved methods of non-oral neonatal feeding: A commentary
- DOI:
10.1016/s0022-3476(73)80425-1 - 发表时间:
1973-06-01 - 期刊:
- 影响因子:
- 作者:
William C. Heird - 通讯作者:
William C. Heird
Effect of Quantity of Concomitant Energy (E) Intake of Low Birth Weight (LBW) Infants on Leucine Oxidation † 1388
- DOI:
10.1203/00006450-199704001-01407 - 发表时间:
1997-04-01 - 期刊:
- 影响因子:3.100
- 作者:
Sudha Kashyap;Kyoko Okira-Kist;William W. Wong;Farook Jahoor;William C. Heird - 通讯作者:
William C. Heird
William C. Heird的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William C. Heird', 18)}}的其他基金
IMPACT OF DEVELOPMENT ON PROTEIN UTILIZATION AND GROWTH
发育对蛋白质利用和生长的影响
- 批准号:
8166655 - 财政年份:2009
- 资助金额:
$ 1.46万 - 项目类别:
IMPACT OF DEVELOPMENT ON PROTEIN UTILIZATION AND GROWTH
发育对蛋白质利用和生长的影响
- 批准号:
7950591 - 财政年份:2008
- 资助金额:
$ 1.46万 - 项目类别:
IMPACT OF DEVELOPMENT ON PROTEIN UTILIZATION AND GROWTH
发育对蛋白质利用和生长的影响
- 批准号:
7605857 - 财政年份:2007
- 资助金额:
$ 1.46万 - 项目类别:
COMPARISON OF TWO METHODS FOR STUDYING PROTEIN METABOLISM IN HEALTHY ADULTS
研究健康成人蛋白质代谢的两种方法的比较
- 批准号:
7375048 - 财政年份:2005
- 资助金额:
$ 1.46万 - 项目类别:
IMPACT OF DEVELOPMENT ON PROTEIN UTILIZATION AND GROWTH
发育对蛋白质利用和生长的影响
- 批准号:
7374969 - 财政年份:2005
- 资助金额:
$ 1.46万 - 项目类别:
IMPACT OF DEVELOPMENT ON PROTEIN UTILIZATION AND GROWTH
发育对蛋白质利用和生长的影响
- 批准号:
7206773 - 财政年份:2004
- 资助金额:
$ 1.46万 - 项目类别:
Impact of Development on Protein Utilization and Growth
发育对蛋白质利用和生长的影响
- 批准号:
6681772 - 财政年份:2003
- 资助金额:
$ 1.46万 - 项目类别:
Impact of Development on Protein Utilization and Growth
发育对蛋白质利用和生长的影响
- 批准号:
6785926 - 财政年份:2003
- 资助金额:
$ 1.46万 - 项目类别:
Impact of Development on Protein Utilization and Growth
发育对蛋白质利用和生长的影响
- 批准号:
6920814 - 财政年份:2003
- 资助金额:
$ 1.46万 - 项目类别:
Impact of Development on Protein Utilization and Growth
发育对蛋白质利用和生长的影响
- 批准号:
7270065 - 财政年份:2003
- 资助金额:
$ 1.46万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 1.46万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 1.46万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 1.46万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 1.46万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 1.46万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 1.46万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 1.46万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 1.46万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 1.46万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 1.46万 - 项目类别:
Research Grant